CG Oncology reported Monday that cretostimogene, a cold virus engineered to hit a bladder-tumor mutation and infused via catheter, lowered the risk of tumor recurrence by 68% versus current care in a randomized phase 3 trial of 367 patients with intermediate-risk bladder cancer, a localized form usu